Clinical trials
Skin Neoplasms trials with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
56 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 2 |
| 2006 | 2 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 3 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 5 |
| 2019 | 4 |
| 2020 | 6 |
| 2021 | 4 |
| 2022 | 9 |
| 2023 | 4 |
| 2024 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 56 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Taiwan University Hospital | 4 |
| Al-Azhar University | 2 |
| Bispebjerg Hospital | 2 |
| Central Hospital, Nancy, France | 2 |
| Massachusetts General Hospital | 2 |
| McMaster University | 2 |
| Xiangya Hospital of Central South University | 2 |
| Alberta Health Services, Calgary | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Association of Dermatological Prevention, Germany | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Skin Neoplasms | 56 |
| Melanoma | 13 |
| Basal Cell Carcinoma | 11 |
| Carcinoma, Squamous Cell | 10 |
| Breast Neoplasms | 5 |
| Neoplasms | 4 |
| Esophageal Neoplasms | 3 |
| Neoplasm Metastasis | 3 |
| Skin Diseases | 3 |
| Urinary Bladder Neoplasms | 3 |
Trials
Showing 76 to 56 of 56. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.